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Abstract 
Enterovirus 71 (EV-A71) is one of the major pathogens causing hand, foot and mouth disease (HFMD). 
Some strains can lead to neurological disease and fatality in children. Up to date, there is no 
FDA-approved vaccine to prevent severe HFMD and mortality. Although the inactivated vaccine has 
advanced to production in China, lack of long-term protection and the requirement of multiple boosters 
have necessitated the development of other types of vaccines. Recent studies indicate that cellular and 
not humoral immunity determines the clinical outcome of EV-A71 infections. High levels of cytokines 
such as IL-1β, IL-6, IL-10 and IFN-γ tend to correlate with clinical severity in patients with pulmonary 
edema and encephalitis. The live attenuated vaccine may serve as the preferred choice as it can induce 
excellent humoral and cellular immunity as well as live-long immunity. Expression of certain HLA alleles 
such as TNF-α promoter type II (-308 allele), HLA-A33 and HLA-DR17 responses have been linked to 
severe HFMD. However, the high variability of MHC genes could restrict T cell recognition and be a 
major obstacle in the design of peptide vaccines. Hence, the development of a T cell universal vaccine 
(incorporating both CD4+ and CD8+ T cell epitopes) that induces broad, multifunctional and 
cross-reactive CD8+ T cell responses maybe desirable. 
Key words: Hand, foot and mouth disease; enterovirus 71; cellular immunity; immunogenicity. 
Introduction 
Vaccines against the Hand, Foot and Mouth 
Disease (HFMD) are highly desirable as HFMD has 
evolved to become a life-threatening epidemic, 
ravaging lives of young children in cyclical epidemics 
in the Asia Pacific. In 2017, a total of 1,952,435 cases of 
HFMD were reported in China [1]. With rising 
concern about the virulence of EV-A71, there is an 
urgent need for a vaccine against EV-A71 to be 
produced that is approved by the FDA. 
Pharmaceutical companies such as CAMS, Vigoo and 
Sinovac have obtained drug certificates and 
production licenses by China’s FDA for the 
inactivated vaccine (IV) against sub-genotype C4a [2].  
Sinovac reported that the efficacy of their 
inactivated vaccine (IV) against EV-A71-associated 
hospitalization and HFMD cases with neurologic 
complications were both 100% [3]. Another study also 
showed an efficacy rate of 95.1% against 
EV-A71-associated HFMD for the second year 
post-vaccination and an overall efficacy rate of 94.7% 
at two years [4]. It would be interesting to perform 
phase IV studies to assess the types of immune 
response and correlates of protection against all 
EV-A71 genotypes/sub-genotypes. Although the IV 
induces good humoral immunity, it may be lacking in 
a strong cellular response, which is needed for 
long-term protection. Therefore, there is a need to 
develop other types of vaccines which can induce 
robust humoral and cellular immunity. The live 
attenuated vaccine (LAV) is an attractive candidate 
against severe EV-A71 as it can induce both humoral 
and cellular immunity, and conferring livelong 
immunity. However, LAVs face potential problems 
such as the risk of reversion to wild type virulence. 
This has been observed in countries which carried out 
vaccination with the Sabin Oral Polio Vaccine. In 
addition, LAVs can be excreted from vaccine 
candidates and this would be dangerous to 
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immunocompromised individuals who have not 
received the polio vaccine [5]. 
As there have been concerns about genetic 
stability of LAV, recent studies have focused on 
another type of experimental vaccine that is devoid of 
genetic material. They are the virus-like particles 
(VLPs) that resemble the authentic, native virus in 
morphology, capsid protein and protein composition. 
However, they do not contain any nucleic acid 
material and would allay fears of genetic stability and 
risk of virulent revertants. Bivalent VLPs that 
replaced the SP70 epitope within the VP1 capsid 
protein of EV-A71 with that of CV-A16 have been 
designed. These ChiEV-A71 VLPs produced in 
Saccharomyces cerevisiae demonstrated similarities in 
morphology and protein composition as the EV-A71 
VLPs. BALB/c neonatal mice immunized with the 
ChiEV-A71 VLPs showed strong cellular immunity as 
indicated by the enhanced production of IFN-γ, IL-2, 
IL-4, and IL-6 in splenocytes. In addition, passive 
immunization with anti-ChiEV-A71 VLP sera 
conferred full protection against lethal challenges 
with both CV-A16 and EV-A71 in neonatal mice [6].  
Three-dimensional bivalent EV-A71/CV-A16 
VLPs utilizing a baculovirus-insect cell expression 
system have been reconstructed and these structures 
resembled natural empty particles of EV-A71 and 
135S-like expanded particles of CV-A16. The 
cryo-electron microscopy results also showed that the 
linear neutralizing epitopes and conformational 
epitopes were well preserved in the bivalent VLPs. In 
addition, immunogenicity tests were carried out in 
mice with the monovalent EV-A71 VLPs, monovalent 
CV-A16 VLPs and bivalent EV-A71/CV-A16 VLPs. 
Mice immunized with the VLP bivalent/composite- 
adjuvant (alum and CpG-oligodeoxynucleotides) 
vaccine was able to induce high NtAb titers ranging 
from 1:160 to 1:320 against four strains of EV-A71 
(804232Y, 8052303F, 804251Y, 8061001Y) and two 
strains of CV-A16 viruses (705212F, 705213F) [7]. 
Nevertheless, there remains considerable interest 
as to which HFMD-causing pathogen should be 
included in a bivalent or trivalent vaccine. As EV-A71, 
CV-A6, CV-A10 and CV-A16 were found to 
co-circulate during HFMD outbreaks and most of the 
cases were due to EV-A71 and CV-A16, it would be 
desirable for a bivalent EV-A71/CV-A16 vaccine to be 
produced [8]. In addition, the bivalent vaccine should 
be able to protect against the EV-A71 sub-genotype C4 
or B4 as these sub-genotypes were the predominant 
ones causing fatal HFMD. Moreover, neutralizing 
antibodies (NtAbs) elicited by C4 and B4 have been 
found to cross neutralize against other EV-A71 
sub-genotypes [9, 10]. This greatly simplifies the 
choice of vaccine strain for EV-A71 as immunization 
with one sub-genotype could potentially cross-protect 
against all other sub-genotypes. This is in contrast to 
the polio vaccine whereby 3 serotypes were required 
to construct the oral polio vaccine. In addition, the 
chosen strain should be able to grow to high titers in a 
FDA approved cell line. These studies could provide a 
reference to the design of future multivalent vaccines 
against EV-A71 and other Coxsackieviruses as a safe 
and cost-effective EV-A71 vaccine with broad 
cross-protection. 
T Cell Immunity against EV-A71 
Research has indicated that cellular and not 
humoral immunity determines the clinical outcome of 
EV-A71 infections. There was no difference in the 
level of NtAb titers between mild, severe and fatal 
HFMD cases [11]. There remains concern about the 
development of vaccines that do not elicit cellular 
immunity but only induces humoral immunity. For 
example, the IV is often a poor inducer of T cell 
responses. There is no viral replication in an IV and 
therefore, there is reduced antigen to sustain an 
extended antigen response [12]. IVs are deemed 
partially successful as it is based solely on 
antibody-mediated protection. Although NtAbs are 
very efficient in preventing the progression of viral 
infections, there may be too many surface proteins of 
viruses that will evolve on a continual basis and this 
could cause viral escape [13]. The research and 
development of successful vaccines would need the 
production of strong and robust T cell responses since 
cytotoxic CD8+ T cell responses are responsible for the 
clearance of viral infection [14]. 
T cells can decrease or eradicate viral 
multiplication upon infection. In particular, CD4+ T 
cell memory can be life-long and it is intriguing that 
after in vitro re-stimulation, there was detection of 
CD4+ T cells for up to 50 years after smallpox 
vaccination [15]. Viruses can enter cells via two routes 
whereby some can infect cells directly. In the first 
route, antigen presenting cells (APCs) like dendritic 
cells (DCs) and macrophages are able to process viral 
proteins into peptide fragments that would be 
presented by MHC I molecules to naïve CD8+ T cells 
[Fig. 1(I)]. In the alternative route for viral entry, DCs 
can also uptake viral particles or remnants of 
viral-infected cells [Fig. 1(II)]. Viral antigens during 
proteolytic processing can be loaded onto MHC I 
molecules via the cross presentation pathway [Fig. 
1(III)]. This pathway would mean that such peptides 
could also be loaded onto MHC II molecules [13].  
Some CD4+ T cell subsets such as T follicular 
helper (TFH), Th1, Th17 and cytotoxic CD4+ T cells 
have vital antiviral roles. Such antiviral functions 
range from the production of cytokines/chemokines 
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(IFN-γ, TNF-α) to direct cytotoxic effects on viral 
infected cells. Memory CD4+ T cells have an added 
protective advantage over naïve cells as they can elicit 
an early innate inflammatory response in tissues that 
are involved in viral control such as faster activation 
of B cells. This would result in a faster and more 
robust antiviral immune response. In addition, 
secondary effectors derived from memory CD4+ T cell 
precursors have more direct antiviral potential than 
primary effectors originating from naïve CD4+ T cells. 
Therefore, a synergistic mechanism of intricate CD4+ 
T cell subsets would indeed provide an impressive 
level of viral control. More ex vivo/in vivo studies 
should be carried out to comprehend the full potential 
of memory CD4+ T cells in the design of better 
vaccines [16]. 
The role of TFH cells in EV-A71 infected children 
has not been explored in depth. Elevated levels of 
circulating TFH cells with high inducible costimulatory 
(ICOS) and programmed death-1 (PD-1) expression 
were significantly correlated with serum-specific 
NtAb-EV-A71 levels, in addition to high 
concentrations of IL-21 and IL-6 in EV-A71 infected 
patients. In addition, the IL-6 and IL-21 mRNA 
expression in the peripheral blood mononuclear cells 
(PBMCs) were also significantly greater as compared 
to the healthy volunteers. This implies that TFH cells 
and associated cytokines are vital in the regulation of 
humoral responses in severe HFMD infection [17]. Up 
to date, little is known about the protective T cell 
immunity in EV-A71 infected individuals. An ex vivo 
IFN-γ ELISPOT assay was performed in EV-A71 
infected children and in healthy adult controls of the 
CD4+ and CD8+ T cell responses to overlapping 
peptides encompassing the VP1 and 3Dpol regions. 
Most of the severe HFMD patients showed 3Dpol 
CD4-dependent responses, whereas there was a small 
group of infected children who had VP1 and 3Dpol 
CD8-dependent responses. The authors discovered 
that no VP1-specific CD4-dependent T cell response 
was detected in 30% of the adult controls. They also 
characterized 24 peptides consisting of potential CD4+ 
T cell epitopes [18]. Their observations surmised that 
it would be predominantly the 3Dpol CD4-dependent 
T cell responses that were vital in protective 
immunity against EV-A71 infections. 
Cellular Immunity and Vaccine Design 
Cellular cytokines such as interferon-gamma- 
inducible protein-10 (IP-10), IFN-γ and monokine 
induced by gamma interferon (Mig) have been found 
to decrease viral load in tissues of EV-A71 infected 
mice. In severe EV-A71 infection, high levels of IP-10 
elevated expressions of Mig, IFN-γ and CD8 T cell 
infiltrated the murine brain. They deduced that IP-10 
was vital for viral clearance in tissues and increased 
survival rate of mice [19, 20]. There were also 
increased levels of IL-1β, IL-10, MIP-2, TNF-α, IFN-γ 
 
Figure 1. Routes of presentation of viral peptides on APCs [13]. Some viruses can infect cells and replicate prior to being degraded into peptide fragments. Some 
fragments will be presented on MHC class I molecules to naïve CD8+ T cells. Binding of the TCR to the MHC class I-peptide complex activates the CD8+ T cells and releases 
cytotoxic granules and cytokines (TNF-α and IFN-γ). Some viral peptides can be presented on MHC class II molecules in parallel by APCs. The TCR of naïve CD4+ T cells can 
recognize MHC class II-peptide complexes on APCs and differentiate into Th1 and Th2 cells. Copyright 2014. Frontiers Media SA. Permission attained on May 25, 2017 by author 
Rosendahl Huber and Frontiers in Immunology, in accordance with the Creative Common Attribution licence (https://creativecommons.org/licenses/by/4.0/). Disclaimer: All 
software used on the site, and the copyright in the code constituting such software, is the property of or is licensed to Frontiers and its use is restricted in accordance with the 
Frontiers Terms and Conditions. All copyright, and all rights therein, are protected by national and international copyright laws. 
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and IL-6 in immuno-deficient AG129 mice that were 
afflicted with severe HFMD caused by EV-A71 [21]. 
Ideally, a vaccine should contain multiple CD4+ 
and CD8+ epitopes that are specific for different 
MHC-molecules [13]. This would be beneficial as the 
CD4+ epitopes would provide co-stimulation during 
CD8+ T cell priming and this would lead to the 
formation of memory CD8+ T cells [22]. The presence 
of CD4+ T cells optimizes expression of CD8+ T cells 
and enhances the level of NtAbs [14]. Stimulation of 
CD4+ T cell responses have been detected after 
infections by viruses such as the poliovirus [23], 
influenza [24], dengue [25], and Epstein Barr viruses 
[26]. Other studies found that the protection conferred 
by these vaccines did not require the presence of 
NtAbs but only occurred in a unique T-cell mediated 
condition [27]. Existing cytotoxic CD4+ T cells induced 
in response to influenza H3N2 or H1N1 were linked 
with milder illness in the absence of NtAbs.  
There are a few requirements for an effective 
immune response to be elicited against viruses. 
Firstly, there must be an ample number of cytotoxic 
CD8+ T cells to kill virus-infected cells. This was 
exemplified in chimpanzees that were completely 
devoid of CD8+ T cells which could not clear the HBV. 
However, when the CD8+ T cells were re-introduced 
into the primates, the chimpanzees were able to 
completely clear the virus [28]. This shows that CD8+ 
T cells are vital for optimizing the efficacy of a 
vaccine. In addition, a broad T cell response would be 
beneficial. Administration of a vaccine against 
influenza virus that contained multiple epitopes (3LP; 
a mixture of the M1, PA, and NS1 lipopeptides) was 
more effective than a vaccine with a single epitope 
(either M1-LP, PA-LP, or NS1-LP) [29]. Another 
requirement for an efficient antiviral response would 
be the involvement of poly-functional Th1 and Th2 
cytokines. As CD8+ T cells are the primary cell types in 
clearing virus infections, they are characterized by the 
Th1 cytokines being produced (IFN-γ, IL-2, TNF-α, 
MIP-1β). IFN-γ has been found to increase the 
cytotoxic function of CD8+ T cells, whereas TNF-α 
causes apoptosis of viral-infected cells. Such 
poly-functional responses are known to elicit more 
extensive T cell dissemination and protection against 
viral infection [14].  
In addition, increasing number of studies are 
illustrating that EV-A71 inhibits production of IFNs at 
different points in the cell signaling pathways. For 
example, the EV-A71 3Cpro inhibited IFN synthesis in 
mice, by inducing cleavage of IRF7 that inactivated 
IFN production [30, 31]. The EV-A71 2A proteinase 
could also decrease production of IFN but through a 
different mechanism. It was postulated that this 
proteinase could directly cleave the Mitochondrial 
Antiviral signaling protein (MAV) into 3 cleavage 
fragments that were not able to activate type 1 IFN 
production [32]. Interestingly, the 2A proteinase could 
also degrade IFN-1 receptor (IFNAR1), thereby 
inhibiting IFN-mediated phosphorylation of Janus 
activated kinase (Jak)-signal transducers and 
activators of transcription (STAT) [33]. However, 
contrasting results were attained by Liu et al. (2014) 
when they deduced that EV-A71 did not inhibit 
IFNAR1, but inhibited JAK1-STAT signaling through 
the down regulation of JAK1 [34]. Hence, further 
studies should be carried out to explore the effect of 
EV-A71 towards IFNAR1 and downstream signaling 
pathways. 
It has been demonstrated that EV-A71 has the 
capability to infect CD14+ cells and to migrate to other 
target tissues such as the cardiovascular and 
lymphatic tissues. This could occur through the 
circulation of the virus in the blood and lymphatic 
systems. CD14 is a pattern recognition molecule and 
is a major hallmark of immature denditric cells and 
monocytes. CD14+ cells could stimulate the 
replication of T cells, hence modulated the cytokine 
expression profiles after EV-A71 infection. With the 
back-transfusion of EV-A71-infected CD14+ cells in 
donor rhesus monkeys, an adaptive immune response 
was elicited. There was significant increase in the 
levels of functional cytokines such as IFN-γ, IL-6 and 
TNF-α. The authors hypothesized that the immune 
responses activated by EV-A71-infected CD14+ cells 
was indicative of a skewed Th2 response [35].  
A panel of 120 immune factors in HFMD cases 
was screened and the macrophage inflammatory 
protein (MIP-1β), granulocyte-macrophage colony 
stimulating factor (GM-CSF), granulocyte-colony 
stimulating factor (G-CSF), monocyte chemoattractant 
protein-1 (MCP-1), IL-2, IL-23, and IL-33 secretions 
were significantly elevated in severe/very severe 
patients who had neurological damage in comparison 
to healthy subjects. Hence, these chemokines could 
serve as potential predictors for EV-A71-afflicted 
brainstem encephalitis and pulmonary edema [36]. 
The elevation of IL-23 and IL-33 in severe patients was 
not surprising as these cytokines have been associated 
with cell-mediated immune responses such as Th2 cell 
polarization [37]. Interestingly, out of the 7 elevated 
immune mediators in severe patients, G-CSF and 
MCP-1 were markedly increased in the CSF than in 
the plasma. These chemokines could be dominant 
mediators elicited during neurological damage in the 
CSF as chemokines are usually elicited within a few 
hours after injury in the central nervous system (CNS) 
cells to activate mononuclear phagocytes [38]. Hence, 
these chemokines are integral components of the 
adaptive immunity to decrease severe tissue damage. 
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In another study measuring 50 cytokines/ 
chemokines in the serum samples of HFMD patients 
and controls, there were elevated levels of TNF-α, 
IL-12p40, IL-3 and IL-6 in patients who displayed 
relatively mild HFMD symptoms, indicative of 
systemic inflammation. For patients who did not 
exhibit any cardiopulmonary symptoms, there was a 
reduction in other biomarkers such as soluble 
ICAM-1, CXCL-1, IL-1Ra, IL-8, IL-16, and CCL27. 
There was no change in expression levels of HFMD 
biomarkers such as CD-107a, IFN-γ or IL-2 after 
patients were treated with intravenous 
methylprednisolone. Instead, they registered an 
increase in expression levels of IL-17A which was 
unexpected as this cytokine was not a 
HFMD-associated biomarker [39]. There was 
significant correlation between cytokines such as 
TNF-α, IL-10, IL-4, IL-6, and IFN-γ with HFMD 
severity. Higher levels of these HFMD-associated 
biomarkers were detected compared to patients who 
showed mild symptoms, especially during the 2-5th 
day after disease onset. Their findings were indeed 
implicative that TNF-α, IL-4, IL-6, IL-10 and IFN-γ 
were involved in disease severity [40]. Another study 
concurred that there were elevated levels of IL-10, 
IL-13, and IFN-γ in patients presenting symptoms of 
brainstem encephalitis [41].  
Hence, a simple parameter to evaluate a good 
vaccine-elicited response is the measurement of 
multifunctional cytokines such as IFN-γ, TNF-α, IL-2 
and IL-6. Particularly, TNF-α and IFN-γ have been 
shown to mediate clearing of a wide range of 
microorganisms, from viruses, parasites, fungi to 
bacteria [42, 43]. IL-2 is vital to promote the expansion 
of CD8+ and CD4+ T cells, either in a paracrine or 
autocrine way, which could increase CD8+ T cell 
memory function [44]. IL-6, in particular has been 
closely associated with patients with pulmonary 
edema and encephalitis [45]. In addition, the 
measurement of CD107a could also be an indirect 
gauge of the levels of degranulation, indicative of the 
cytolytic activity of CD8+ T cells via release of 
granzymes. This is because CD107a is expressed on 
CD8+ T cell surface, following activation with a 
corresponding peptide, in concordance with the 
production of intracellular IFN-γ [46]. Hence, the 
measurement of the recurrence of multi-functional 
CD8+ T cells that elicit 2 or more of such cytokines are 
invaluable. In fact, improved control of viral diseases 
such as influenza, Hepatitis C and HIV has been 
attributed to the increase in multifunctional T cells 
[47].  
It is increasingly clear that there is a need to elicit 
both quality CD4+ and CD8+ T cell responses in 
vaccine development. In the first comprehensive 
study of EV-A71-responsive cellular immunity in 
healthy human volunteers, majority of the broad T 
cell responses (approximately 93%) were 
predominated by antigens (Ag) from the VP2 as 
compared with Ags from VP1, VP3 and VP4 after in 
vitro expansion, consistent with the high NtAb levels 
(Fig. 2). Interestingly, these cellular responses were 
mainly CD4+ T cell-dependent. Upon further 
investigation, the broad EV-A71-responsive cellular 
responses were mainly by IFN-γ-secreting cells and 
not by the IL-2-secreting cells. The authors utilized a 
panel of 110 overlapping peptides encompassing the 4 
structural Ags of EV-A71 to investigate existing T cell 
epitope profiles of volunteers in a HLA-independent 
restricted methodology [48]. Hence, the dominant 
immunogenicity of the VP2 Ag provides vital 
connotations in the growing knowledge of EV-A71 
cellular immune responses as intensive research has 
been conducted on the VP1 Ag as well as some 
HLA-class II-restricted T cell epitopes [49].  
In a LAV, knowledge of the location of CD4+ and 
CD8+ epitopes are important. For example, 
characterization of T cell epitope reactivity towards 
the dengue virus (DENV) genome has been carried 
out and 30 novel T cell epitopes were discovered in 
Asian dengue patients, out of which 21 were CD8+ 
epitopes and the remaining were CD4+ epitopes. In 
addition, they found that the CD4+ T cells recognize 
the same viral proteins as the B cells (envelope, 
capsid), whereas the CD8+ T cells preferred the 
nonstructural proteins NS3 and NS5. The differential 
recognition of viral proteins by the CD4+ and CD8+ T 
cells could possibly be attributed to the dosage and 
timing of viral protein production [50]. The authors 
hypothesize that peptide recognition by CD4+ T cells 
are in the context of antigen-specific B cells. Such 
information is vital in vaccine design as it may be 
necessary to include nonstructural proteins, 
particularly NS3 and NS5 in their DENV vaccine 
formulations to elicit robust CD8+ T cell response [51]. 
Although NtAbs are vital in the prevention of 
infection, studies have shown that it would be the 
CD8+ T cells that are able to contain viral load and 
prevent disease progression into more fatal cases [14]. 
It can be observed that in the most fatal 
EV-A71infections with pulmonary oedema, blood 
samples showed higher levels of cellular IL-1β, IL-6 
and tumor necrosis factor-α (TNF- α) [11]. High CSF 
levels of IL-6 have been shown to be correlated with 
disease severity. This explains why fatal HFMD 
infections generally afflict the very young as they 
would have weaker cellular immunity although they 
may have some maternal EV-A71 NtAbs. This has led 
to an increased understanding about disease 
progression of EV-A71 post-infection, which range 
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from an absence of symptoms (~71%) to fatality 
(~0.05%) [52]. In fact, polymorphism of the cytotoxic T 
lymphocyte protein-4 (CTLA-4) has been linked to 
changes in cellular immunity which is correlated to 
disease severity. The CTLA-4 polymorphism could 
contribute towards a higher frequency of G/G allele 
in patients with meningoencephalitis, compared to 
those without this condition. They postulated that 
children with CTLA-4 polymorphism, in combination 
with an altered cellular but not humoral response, 
could be associated with severe EV-A71 [53].  
HLA-DR variation and peptide vaccine 
design 
The peptide vaccine is an emerging experimental 
vaccine worldwide due to its low cost, easy 
production and is a well-defined epitope-based 
vaccine. Although peptide vaccines can elicit 
production of antigen-specific T cells, it has low 
immunogenicity which could pose as a major 
challenge. Hence, it could be formulated with 
FDA-approved adjuvants or delivered with 
nanoparticles. The immunogenicity of peptide 
vaccines against influenza virus could be increased by 
augmenting the affinity for the MHC molecules 
though exchanging amino acids in wild type 
sequences with non-proteogenic amino acids. This in 
turn increased the level of CD8+ T cell response. 
Specifically, HLA-A*0201 epitopes GILGFVFTL, 
FMYSDFHFI and NMLSTVLGV were chosen and for 
each epitope, chemically altered peptide ligands 
(CPLs) that showed greater binding affinity than their 
wild type was manufactured. They showed that 50% 
CPLs of each epitope demonstrated elevated IFN-γ 
levels in the splenocytes of HLA-A*0201 transgenic 
mice that were inoculated with the CPLs. The authors 
demonstrated that this strategy could be extended to 
other alleles and could effectively increase the 
immunogenicity and range of preventive T 
cell-targeted peptide vaccines [54]. 
Hence, it was a natural progression in the design 
of peptide vaccines that strong T cell epitopes were 
introduced in its construction. Researchers identified 
T cell epitopes in the C terminal of the CS protein that 
were exposed by multiple MHC class II molecules 
which could be recognized by CD4+ T cells from 
humans and mice [55]. That was remarkable as 
conventionally, one MHC molecule could only at 
most bind to a few peptides [56]. The uniqueness of 
such an approach led to the characterization of many 
 
Figure 2. Diverse distribution of VP2-specific T cell immunogenic regions [48]. The T cell responses were specified to a region of 40–50 aa for VP1 (A), VP2 (B), VP3 
(C), and VP4 (D). The y-axis displays the strength of responses as represented by SFCs per 105 PBMCs. The x- and z-axes show the peptide spanning region and subjects, 
respectively. The magnitude of responses to VP2 were more diversely distributed along the Ag (B), whereas there was an intensely focused distribution of responses to the 
central region in VP1, VP3, and VP4. Copyright 2013. The American Association of Immunologists, Inc. Permission obtained on April 12, 2017 from the American Association of 
Immunologists, Inc. 
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more epitopes displaying similar properties [57]. 
Hence, these epitopes were referred to as universal 
CD4+ T cell epitopes. With such universal epitopes, 
there could be strong humoral and cellular immunity 
being induced in individuals with diverse MHC 
haplotypes. This was exemplified by a second 
generation malaria vaccine that included a universal 
CD4+ epitope and the CS protein that could elicit 
broad-based immunity [58]. With the existence of 
universal CD4+ T cell epitopes, this has greatly 
overcome the problem of the restriction of T cell 
recognition of antigens due to the high variability of 
human MHC genes.  
Several human leukocyte antigen (HLA) alleles 
are correlated with more severe disease and weaker 
CD8+ responses. HLA-A*0101 and A*2402 restricted 
responses had the lowest anti-DENV response, 
whereas HLA-B*35:01 restricted responses displayed 
the highest magnitude of anti-DENV response [59]. It 
has been reported that HLA-A and not HLA-B is 
linked to Dengue Hemorrhagic Fever (DHF) [60]. This 
might explain why individuals who carry 
non-protective alleles (HLA-A) and 
disease-exacerbating antibodies developed DHF with 
secondary DENV infection. HLA A*24:02 and A*02:01 
were associated with lower anti-DENV response [59]. 
Their results were compared with blood donors from 
a Sri Lankan population and there was a strong 
relationship between the magnitude of CD8+ T cell 
responses and HLA allele restriction. This implies the 
effect of HLA genes on the nature of cellular 
responses. The poignant observation was that 
uniquely, the B*35:01 DENV-specific T cells were 
linked with elevated levels of the programmed death 
1 protein (PD-1). PD-1 is a member of the CD28 
superfamily and is a marker on virus-specific CD8+ T 
cells to measure the degree of T cell activation. It is 
believed that PD-1 may prevent excessive tissue 
damage while preserving anti-viral function. The 
expression of certain HLA alleles significantly 
influenced the spread and intensity of CD8+ T cell 
responses [61].  
A vital factor in the design of peptide vaccines 
would be HLA-DR variation. Some notable examples 
would be that for Hepatitis B. About 5-10% of 
vacinees had poorly induced vaccine responses which 
possibly could be attributed to the presence of 
HLA-DRB1*0701 and DQB*0202 haplotypes in the 
poor responders [62]. As for the measles vaccine, the 
predominant limiting factor for robust T cell response 
towards the measles virus phosphoprotein (MV-P) 
and nucleoprotein (MV-N) would be the presence of 
HLA-DRB1 in vacinees who respond weakly towards 
the vaccination [63]. Hence, it can be surmised that 
varying MHC class II variants have different peptide 
binding preferences and this would aid in the 
prediction of CD4+ T cell responses to vaccine 
challenge. Therefore, it is vital to define targets of 
CD4+ T cell responses that are induced by vaccination. 
Studies to investigate MHC specificity are of 
paramount importance as peripheral blood 
mononuclear cells (PBMCs) from varied individuals 
typically express multiple MHC class II proteins. In 
addition, epitope validation studies such as isolation 
of epitope-specific T cell lines and research on 
cross-reactivity with epitopes processed from viruses 
can contribute towards knowledge on MHC 
specificity [64].  
The importance of CD8+ T cell responses have 
been illustrated by numerous studies that HIV escape 
mutations frequently happen at HLA-binding sites 
specific for CD8 epitopes. For example, certain 
HLA-alleles are correlated with protection from HIV 
disease development and there exists a transient 
relationship between an increase in CD8+ T cells and 
reduction in viral titer [65, 66]. In addition, a 
univariate analysis of 219 EV-A71 infections were 
discovered and TNF-α promoter type II (-308 allele), 
HLA-A33 and HLA-DR17 were linked to complicated 
severe cases. Amongst the 3 alleles, patients with 
HLA-A33 were significantly most susceptible to 
EV-A71 infection when compared to patients carrying 
the rest of the alleles. Interestingly, HLA-A33 is a rare 
genotype among Caucasians but is a common 
genotype among Asians [67], hence the study 
increases our understanding on the frequent 
occurrence of EV-A71 cyclical epidemics affecting the 
Asia Pacific region. Indeed, immune factors such as 
varying clinical and histopathological CD4+ T 
responses were able to mediate tissue damage caused 
by virulent EV-A71 strains [68]. It is intriguing that 
different EV-A71 genotypes can produce mild or 
severe symptoms in different individuals, dependent 
on the genetic makeup and immune status of 
individuals.  
 Although many studies have elucidated that 
VP1 is the major target of NtAb in mice, Tan et al. 
(2013) showed that it was the VP2 Ag that is the 
predominant antigen in eliciting T cell responses in 
humans. Consistent with their study, Wei and 
colleagues (2012) utilized an in silico-predicted 
peptide pool comprising amino acids 176-193 from 
VP2-24, and was able to characterize a highly 
conserved T cell epitope in the VP2. In their study, 15 
epitopes were identified and three (A3, A8 and A14) 
of them were dominant in eliciting CD4+ T cell 
response. Amongst the three, A3 was the most 
predominant epitope and was highly conserved 
among coxsackieviruses that cause HFMD, 
specifically CV-A4, CV-A6, and CV-A16, and it has 
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the ability to attach to multiple HLA-DR (antigen D 
Related) alleles. Interestingly, this A3 epitope, which 
is located in the VP2 capsid, was also highly 
conserved amongst other HFMD-unrelated 
coxsackieviruses, echoviruses and polioviruses. The 
authors also discovered that the CD4+ T cells specific 
for EV-A71, A3 could cross-react with PV A3v 
epitope, implicating the possibility for immune 
responses that are cross-reactive and related to PV 
immunization or other enteroviruses in early 
childhood. There could be potential 
immuno-regulation of subsequent CD4+ T cell 
response to EV-A71 infection or vaccination [69]. 
As the LAV has been very successful in reducing 
rate of poliomyelitis worldwide, studies have shown 
that the LAV against EV-A71 was able to induce a 
strong immune response. Similar to an infection with 
PV, infection with EV-A71 can be easily preventable 
by LAVs that can induce both cellular and humoral 
immunity as well. There were high levels of CD69+ 
and CD3+ T cells in mice administered with the 
EV-A71 LAV upon challenge with the wild type virus. 
As EV-A17 and CV-A16 share many common 
biological and molecular characteristics, the authors 
repeated the immunization experiments with a 
CV-A16 LAV. It was expected that this would yield 
similar results as exemplified by an elevated 
expression of CD69+ and CD3+ T cells in the 
CV-A16-immunized mice after EV-A71 challenge [70].  
There remains considerable interest in 
understanding the varying cellular responses in 
individuals vaccinated with the LAV against mumps. 
A research group carried out HLA genotyping of 346 
healthy children who had been administered with 2 
doses of the mumps LAV. Interestingly, there was 
significant immune response variations of some HLA 
class II alleles to the mumps LAV. Examples of such 
HLA alleles would be the DQA1 (*0101, *0105, *0401, 
and *0501) and DRB1 (*0101, *0301, *0801, *1001, 
*1201, and *1302). There were significant cellular and 
humoral immune responses being elicited, specifically 
by minor alleles for four single nucleotide 
polymorphisms (SNPs) within the IL-12RB and 
IL-10RA genes. Their findings highlighted the 
association between HLA variations and its varying 
effects on the immune response induced by the 
mumps LAV [71].  
Conclusion 
The use of the IV could prevent mild infections 
caused by EV-A71 but there remains a need for 
further research to evaluate the efficacy of the IV in 
comparison with the VLPs and LAVs to confer 
protection against severe HFMD. Having the IV as the 
only vaccine candidate that is protective against mild 
HFMD may not be optimal. In addition, phase IV 
clinical trials should be conducted to gauge long-term 
efficacy and optimization of the IV over a much larger 
target population. There remains a greater need to 
understand the role of cellular immunity such as 
CD4+ and CD8+ T cells in the immuno-protection of 
EV-A71. Identification of broad-based (cross-reactive) 
immunogenic CD8+ T cell epitopes that will induce 
more cytotoxic CD8+ T cell responses has to be carried 
out. The characterization of universal CD4+ T helper 
and CD8+ T cell epitopes to elicit broad-based 
immunity in individuals who express certain MHC 
allelic variants will contribute to the rational design of 
an optimal EV-A71 peptide vaccine that could trigger 
immune responses from both cellular and humoral 
systems. The link between gene polymorphisms and 
HLA variations to elicit humoral and cellular immune 
responses may provide further insights into the 
design of an ideal vaccine targeting EV-A71 causing 
severe HFMD.  
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